Registration of phase 3 crossover trials on ClinicalTrials.gov

被引：0

作者：

Lijuan Zeng

Riaz Qureshi

Shilpa Viswanathan

Lea Drye

Tianjing Li

机构：

[1] Statistics Collaborative,Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology

[2] Inc,Department of Ophthalmology

[3] Johns Hopkins Bloomberg School of Public Heath,undefined

[4] IQVIA,undefined

[5] Blue Cross Blue Shield Association,undefined

[6] School of Medicine,undefined

[7] University of Colorado Denver,undefined

来源：

Trials | / 21卷

关键词：

Crossover trials; Trial registration; ClinicalTrials.gov; Longitudinal trial; Data sharing; Trial reporting;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 44 条

[1]

Zarin DA(2008)Moving toward transparency of clinical trials Science 319 1340-1342

[2]

Tse T(2012)Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010 JAMA 307 1838-1847

[3]

Califf RM(2019)Robustness of crossover trials against subject drop-out – examples of perpetually connected designs Stat Methods Med Res 28 788-800

[4]

Zarin DA(2015)Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis PLoS One 10 1-12

[5]

Kramer JM(2015)The method quality of cross-over studies involved in Cochrane Systematic Reviews PLoS One 10 1-8

[6]

Sherman RE(2014)Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications Ann Intern Med 160 477-483

[7]

Aberle LH(2015)Compliance with results reporting at ClinicalTrial N Engl J Med 372 1031-1039

[8]

Tasneem A(2011)The ClinicalTrials.gov results database – update and key issues N Engl J Med 364 852-860

[9]

Godolphin PJ(2020)Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study Lancet. 395 361-369

[10]

Godolphin EJ(2019)CONSORT 2010 statement: extension to randomised crossover trials BMJ. 366 l4378-undefined